Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Argenta and ANTABIO Announce Drug Discovery Collaboration

Published: Friday, February 08, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
Programme will focus on novel antibacterial agents.

Argenta has announced that it has signed a collaboration agreement with ANTABIO.

Under the terms of the agreement, Argenta will provide medicinal chemistry, computer-aided drug design and ADME/PK services, together with its integrated drug discovery expertise, to assist ANTABIO in the identification of novel anti-bacterial agents and discovery of a development candidate that can be progressed into clinical trials.

The collaboration is funded by a Wellcome Trust Seeding Drug Discovery award.

Between 5 and 10% of hospital patients in the US and Europe develop hospital-acquired (nosocomial) infections. The consequences are up to 75,000 deaths per year, 2.5 million additional hospital days due to drug-resistant bacterial infections and an average additional cost of 1.5 billion euros for healthcare systems.

In 2004, the World Health Organization identified infections caused by drug-resistant bacteria as the number one disease requiring priority medicines.

ANTABIO’s first-in-class, small molecule compounds offer a synergistic solution to the shortfall of current antibacterial agents.

In particular, ANTABIO is developing new drugs that will work with existing antibiotics to enable them to regain their activity against multi- or pan-drug resistant Gram-negative pathogens such as NDM-1 bacteria.

ANTABIO’s compounds will also prevent infections caused by virulent and multi-drug resistant bacteria such as Escherichia coli (E. coli) that are responsible for severe nosocomial-acquired infections as well as other common community-acquired conditions like urinary tract infections and food poisoning.

Dr John Montana, Managing Director of Argenta, commented, “Argenta is proud to announce this agreement with ANTABIO, which is the second SDDI-funded collaboration to be disclosed by Argenta in recent months. There is an urgent need for new anti-bacterial drugs and we look forward to working with ANTABIO to progress their compounds rapidly towards pre-clinical candidate nomination”.

“We are very excited to collaborate with Argenta on this SDDI-funded programme” said Dr Marc Lemonnier, CEO of ANTABIO.

Dr Lemonnier continued, “Assembling an expert and complementary drug discovery team is critical when it comes to advancing novel drugs that are so badly needed by patients suffering from life-threatening infections. This joint effort nicely exemplifies our vision of high-value partnering as a key element to deliver tomorrow’s antibacterial agents”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Argenta, Antabio Achieve Milestone in Anti-bacterial Drug Discovery Collaboration
Argenta has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug discovery project funded by the Wellcome Trust.
Monday, March 10, 2014
Argenta Announces Record Year for Peer-Reviewed Publications
Publications have been co-authored with clients such as Genentech, AstraZeneca and Corcept.
Tuesday, December 10, 2013
Argenta Announces Fourth Extension of Drug Discovery Collaboration with Genentech
Agreement covers a portfolio of projects that utilizes Argenta's drug discovery expertise.
Monday, October 14, 2013
Argenta and Pcovery Announce Drug Discovery Collaboration
Under the terms of the agreement, Argenta will provide medicinal chemistry and computer-aided drug design services to assist Pcovery.
Tuesday, July 16, 2013
Argenta Delivers Preclinical Candidate for Wellcome Trust Funded Anti-Aging Project
The three-year project aimed at identifying selective inhibitors of the 11beta-HSD1 enzyme resulted in the identification of a lead candidate.
Tuesday, October 19, 2010
Argenta Expands Collaboration with Genentech to Include BioFocus
Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.
Thursday, September 16, 2010
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
This is the second extension of the contract drug discovery agreement since the first collaboration was announced in December 2005.
Friday, May 22, 2009
Argenta Discovery and Porsolt Join Forces to Provide CNS and Pain Contract Drug Discovery Services
The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for clients.
Wednesday, May 20, 2009
Argenta Discovery and PRECOS Establish Cancer Drug Discovery Alliance
The alliance will provide exceptional cancer drug discovery services and expertise on a fee-for-service basis.
Thursday, February 19, 2009
Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
The Phase II study is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the effect of inhaled ADC4022.
Monday, March 10, 2008
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
The two programmes under the agreement utilize Argenta's expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Wednesday, October 24, 2007
Argenta Discovery Announces Contract Drug Discovery Collaboration with BioTie Therapies
Scientists from the two companies will exploit Argenta’s expertise in medicinal chemistry, computer-aided drug design and early ADME to advance one of BioTie’s therapeutics programmes.
Friday, April 06, 2007
Argenta Announces Collaboration with PainCeptor
Scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design and medicinal chemistry.
Monday, May 01, 2006
Argenta Discovery collaboration with Corcept Therapeutics

Wednesday, May 07, 2003
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos